8-K: Mersana Therapeutics Acquired by Day One Biopharma

Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc. for $25.00 per share in upfront cash plus contingent value rights worth up to an additional $30.25 per share.

Summary

• Mersana Therapeutics, Inc. (the Company) has been acquired by Day One Biopharmaceuticals, Inc. (Parent) through its subsidiary, Emerald Merger Sub, Inc. (Purchaser), following a tender offer and subsequent merger.
• The tender offer, which commenced on December 5, 2025, expired on January 5, 2026, with 3,029,135 shares validly tendered and not withdrawn, representing approximately 60.57% of outstanding shares, satisfying the minimum condition.
• Shareholders received $25.00 per share in upfront cash consideration, plus one non-tradeable contingent value right (CVR) per share, which offers the right to receive up to an aggregate of $30.25 per share in cash upon the achievement of specified milestones related to the drug candidate Emi-Le (emiltatug ledadotin, XMT-1660).
• The merger was consummated on January 6, 2026, with Mersana Therapeutics, Inc. surviving as a direct wholly-owned subsidiary of Day One Biopharmaceuticals, Inc.
• As a result of the merger, Mersana's common stock was delisted from The Nasdaq Stock Market LLC, and the company intends to terminate its SEC registration and reporting obligations.
• All outstanding stock incentive plans and the employee stock purchase plan were terminated, and equity awards were converted into cash or CVRs based on their exercise price relative to the upfront cash consideration.
• The Company's board of directors and all incumbent officers resigned, with new directors and officers from Purchaser (Charles N. York II and Adam Dubow) taking their places, effective as of the merger's completion.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of an acquisition at a premium, offering immediate cash and significant potential upside through CVRs for former shareholders. While the company ceases independent operations, the transaction provides a favorable outcome for investors.

Positives

• Shareholders received a significant upfront cash payment of $25.00 per share, representing a premium.
• Contingent Value Rights (CVRs) provide shareholders with potential additional payments of up to $30.25 per share, offering upside exposure to the future success of Emi-Le.
• The acquisition provides a clear exit strategy and liquidity for Mersana shareholders.
• The merger was funded by Day One Biopharmaceuticals' cash on hand, indicating financial stability for the transaction.

Negatives

• Mersana Therapeutics, Inc. ceases to be an independent publicly traded company, leading to its delisting from Nasdaq and termination of SEC reporting.
• Out-of-the-Money Options (exercise price equal to or greater than the upfront cash consideration) were cancelled without consideration if not exercised by December 29, 2025.
• The CVRs are non-tradeable, limiting liquidity and the ability for holders to realize their value before milestone achievement.
• Achievement of CVR milestones is contingent on future events and Parent's 'Commercially Reasonable Efforts,' which may not guarantee success or continued development of Emi-Le.

Risks

• Milestone payments under the CVRs are contingent upon the achievement of specific development and commercial milestones for Emi-Le, which are not guaranteed and may not occur by their respective end dates.
• Parent's obligation to use 'Commercially Reasonable Efforts' for Emi-Le's development and commercialization may allow for ceasing such activities under certain business judgments, potentially impacting CVR value.
• The CVRs are non-tradeable, meaning holders cannot sell or transfer them (except for Permitted Transfers), limiting liquidity and the ability to realize value prior to milestone payments.
• CVR holders have no voting rights, dividend rights, or equity interest in Parent or the Surviving Corporation, and no interest accrues on potential milestone payments.
• Payments under the CVRs are subject to applicable tax withholding, which may reduce the net amount received by holders.

Future Outlook

The future outlook for former Mersana shareholders is tied to the successful development and commercialization of Emi-Le by Day One Biopharmaceuticals. The CVRs provide potential future cash payments contingent on achieving specific regulatory and commercial milestones for Emi-Le, including breakthrough therapy designation, first patient dosing in a registrational trial, FDA approval for ACC-1, first commercial sales in Europe and Japan, and reaching annual net sales targets of $100 million, $200 million, and $300 million by specified end dates. Day One is obligated to use 'Commercially Reasonable Efforts' to achieve these milestones.

Management Comments

• The resignations of the former directors were tendered in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company's operations, policies or practices.

Industry Context

This acquisition represents a common strategy in the biotechnology and pharmaceutical industry where larger companies acquire smaller, clinical-stage firms to gain access to promising pipeline assets. The use of Contingent Value Rights (CVRs) is a prevalent mechanism in such deals, allowing the acquirer to mitigate risk by tying a portion of the purchase price to the successful achievement of development and commercial milestones for the acquired drug candidate, in this case, Emi-Le. This structure aligns the interests of the selling shareholders with the future success of the asset under the new ownership, reflecting the inherent uncertainties in drug development.

Comparison to Industry Standards

• The structure of the acquisition, combining an upfront cash payment with non-tradeable Contingent Value Rights (CVRs), is a standard approach in biotech M&A, particularly for companies with clinical-stage assets like Emi-Le.
• CVRs are frequently used to bridge valuation gaps between buyers and sellers by sharing the risk and reward associated with future development and commercialization milestones, which is consistent with industry practices for de-risking acquisitions of pipeline assets.
• The specific milestones (e.g., breakthrough therapy designation, first patient dosed, regulatory approvals, and net sales targets) are typical for CVRs in the pharmaceutical sector, reflecting key value inflection points in a drug's lifecycle.
• The 'Commercially Reasonable Efforts' clause, while standard, includes provisions that allow the Parent to cease development under certain business judgments, which is a common, albeit sometimes contentious, aspect of CVR agreements in the industry.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** Received $25.00 per share in upfront cash and one non-tradeable CVR per share, offering potential additional payments up to $30.25 per share based on Emi-Le's future success. The company's stock is delisted, ending public trading.
• **Employees:** Former officers ceased employment, and new management was appointed. Employees holding equity awards had them converted to cash or CVRs, or cancelled if out-of-the-money and unexercised.
• **Customers/Patients:** The development of Emi-Le will continue under Day One Biopharmaceuticals, potentially leading to new treatments for conditions like ACC-1.
• **Creditors:** The acquisition was funded by Day One's cash on hand, and Mersana continues as a subsidiary, implying continuity of obligations under new ownership.
• **Regulatory Authorities:** Nasdaq was notified of delisting, and SEC registration and reporting obligations will be terminated.

Next Steps

• Day One Biopharmaceuticals, Inc. will continue the development and commercialization efforts for Emi-Le, aiming to achieve the specified CVR milestones.
• Mersana Therapeutics, Inc. will be delisted from The Nasdaq Stock Market LLC.
• Mersana Therapeutics, Inc. will file a Form 25 with the SEC to delist and deregister its common stock.
• Mersana Therapeutics, Inc. intends to file a Form 15 with the SEC to terminate its registration under Section 12(g) of the Exchange Act and suspend its reporting obligations.

Key Dates

Keywords

Mersana Therapeutics, Day One Biopharmaceuticals, Merger, Acquisition, Tender Offer, Contingent Value Rights, CVR, Emi-Le, XMT-1660, ACC-1, Biotech, Pharmaceutical, Nasdaq Delisting, Corporate Governance, SEC Filing